A CASE OF FATAL CLINICAL COURSE WITH REVERSIBLE ACUTE CARDIAC FAILURE AND GLUCOSE INTOLERANCE DURING SORAFENIB THERAPY FOR METASTATIC RENAL CELL CARCINOMA

KIMURA TOMOKAZU; KIMURA TOMOKAZU; SUETOMI TAKAHIRO; SUETOMI TAKAHIRO; MIYAGAWA TOMOAKI; TSUTSUMI MASAKAZU

Art

J-GLOBAL ID：201202254479933013 Reference number：12A1285329

A CASE OF FATAL CLINICAL COURSE WITH REVERSIBLE ACUTE CARDIAC FAILURE AND GLUCOSE INTOLERANCE DURING SORAFENIB THERAPY FOR METASTATIC RENAL CELL CARCINOMA

転移性腎細胞癌に対するソラフェニブ投与中に可逆性急性心不全と耐糖能異常をきたし急激な臨床経過で死亡した1例

Publisher site {{ this.onShowPLink() }} Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=12A1285329&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=12A1285329&from=J-GLOBAL&jstjournalNo=F0649A") }}

Author (6)： , , , , ,
Material：
Volume： 58 Issue： 8 Page： 443-446 Publication year： Aug. 31, 2012
JST Material Number： F0649A ISSN： 0018-1994 CODEN： HIKYAJ Document type： Article
Article type：原著論文 Country of issue： Japan (JPN) Language： JAPANESE (JA)

,...
,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=12A1285329&from=J-GLOBAL&jstjournalNo=F0649A") }}

Clinical application of antitumor(=antineoplastic)drugs , Poisoning in general , Cardiovascular system diseases , Metabolic diseases,nutritional diseases in general.

Reference (14)：

1) Wilheim S and Chien DS : BAY 43-9006 : Preclinical data. Curr Pharm Des 8 : 2255-2257, 2002
2) Akaza H, Tsukamoto T, Murai M, et al. : Phase 2 study to investigate the efficacy,safety, and pharmaco-kinetics of sorafenib in Japanese patients with ad-vanced renal cell carcinoma. Jpn J Clin Oncol 37 : 755-762, 2007
3) Awada A, Hendilsz A, Gil T, et al. : Phase 1 safety and pharmacokinetics BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refrac-tory solid tumors. Br J Cancer 92 : 1855-1861, 20054)
4) Ratain MJ, Eisen T, Stadler WM, et al. : Phase 2 placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carci-noma. J Clin Oncol 24 : 2505-2512, 2006
5) Naito S, Tsukamoto T, Murai M, et al. : Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment : final result of phase 2 trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int 108 : 1813-1819, 2011

ｍore...

, , , , , , ,

Return to Previous Page